TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Thomas E Hutson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.